Navigation Links
Onyx Pharmaceuticals Provides Status Update on Carfilzomib
Date:10/7/2010

EMERYVILLE, Calif., Oct. 7 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will delay its New Drug Application (NDA) filing for carfilzomib based on a recent meeting with the Chemistry, Manufacturing and Controls (CMC) review division of the U.S. Food and Drug Administration (FDA).  The FDA has requested additional CMC information related to commercial-scale manufacturing of carfilzomib.  Onyx had previously anticipated filing an NDA by the end of 2010 for accelerated approval of carfilzomib and now expects that its NDA filing for accelerated approval could occur as early as mid-year 2011.

The clinical profile of carfilzomib has not changed, and no new safety signals have been observed. The Phase 3 trials are on schedule and actively enrolling patients, and this change is not expected to impact any of the carfilzomib trials or other development plans.

In preparation for commercial-scale production, the company made manufacturing process enhancements in the production of carfilzomib, which are customary when migrating from clinical to commercial-scale manufacturing.  In a recently completed manufacturing-scale run, the company observed minor variations that are believed to be primarily related to equipment temperature variances.  In response to FDA's request, Onyx is providing the agency with additional CMC information.  Onyx has additional data and is generating more information to share as part of the ongoing dialogue with the CMC review division in preparation for an NDA filing.

"We are confident in the clinical and preclinical data package supporting the carfilzomib NDA and in our manufacturing strategy," said N. Anthony Coles, M.D., president and chief executive officer of Onyx. "We believe that by providing this supportive data, we will strengthen our NDA package, thus enabling us to bring carfilzom
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 According to a ... Identification (RFID) Market (Tags, Readers, Middleware, Printers and Cabinets) ... Forecast, 2014 - 2020" the global radiofrequency identification (RFID) ... and is expected to grow at a CAGR of ... value of USD 5.3 billion in 2020. ...
(Date:8/28/2014)... Aug. 28, 2014  In recognition of the increased ... from the flu, pneumonia, shingles and other illnesses, ... declared September to be Senior Vaccination Month. Because ... is important that adults ages 65 years and ... CVS pharmacists and MinuteClinic nurse practitioners and physician ...
(Date:8/28/2014)... Aug. 28, 2014   Venaxis, Inc.  (Nasdaq:  APPY), ... obtaining FDA clearance for and commercializing its CE Marked ... aiding in identifying children, adolescent, and young adult patients ... for appendicitis, today announced it will present at three ... Annual Global Investment Conference being held in ...
Breaking Medicine Technology:Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 3Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 4Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 5September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 2September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 4Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3
... 26, 2011 In a ceremony today, the University ... Chinese Academy of Sciences (CAS) to develop a joint ... of collaborative research and education in neuroimaging. ... Academy of Sciences Vice President Li Jiayang signed an ...
... 26, 2011 Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX ... overview at the Jefferies 2011 Global Healthcare Conference on June ... The live and archived webcast of the company ... Idenix Investor Center at www.idenix.com . Please log in ...
Cached Medicine Technology:University of Pennsylvania Announces Partnership with Chinese Academy of Sciences for Center of Excellence in Brain Mapping 2
(Date:8/28/2014)... Chicago, IL (PRWEB) August 28, 2014 ... IT Supplement shows that while most hospitals utilize a ... of health care information technology is still a challenge. ... in the August issue of Health Affairs , ... Health Forum’s Health Care Data Center, as well as ...
(Date:8/28/2014)... The New England Journal of Medicine ... trial of a drug shown to safely reduce the ... intranasally infected with respiratory syncytial virus (RSV). ... Tennessee Health Science Center researcher Infectious Disease Specialist John ... , RSV is the most common cause of ...
(Date:8/28/2014)... change is hurting reproduction of the endangered Devils Hole pupfish, ... as few as 35 individuals, new research by the University ... report that geothermal water on a small shelf near the ... the pupfish live is heating up as a result of ... levels. , The hotter water, which now reaches more ...
(Date:8/28/2014)... smoking kills approximately 440,000 Americans each year, according ... It,s the leading cause of preventable death worldwide. ... resort to nicotine replacement therapies. , A ... University of Miami (UM) suggest that small dosages ... harmful to human musculoskeletal system, due to overuse. ...
(Date:8/28/2014)... August 28, 2014 Dr. Paul Kovatis is ... of the U.S. military for his efforts to treat many ... Wounded Warriors Foundation and several other military organizations. Dr. ... Tiger in WWII. Having five members of his immediate ... National Cemetery, it’s no wonder Dr. Kovatis is so dedicated ...
Breaking Medicine News(10 mins):Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 2Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 3Health News:DeVincenzo study breakthrough in RSV research 2Health News:Climate change puts endangered Devils Hole pupfish at risk of extinction 2Health News:Climate change puts endangered Devils Hole pupfish at risk of extinction 3Health News:Are cigarette substitutes a safe alternative? It depends on user habits 2Health News:Are cigarette substitutes a safe alternative? It depends on user habits 3Health News:NJ Top Docs Presents, Dr. Paul Kovatis 2
... There just seems to be no end to the problems caused ... keep stumbling upon one disease after another caused by failure to ... list is asthma. It affects the small tubes - airways - ... ,Those obese have a 50% higher risk of developing asthma, ...
... that ‘bronzed and beautiful’ look. But unfortunately, this is not ... a report published in the Australian and New Zealand Journal ... tanning sessions are alarming. ,This is particularly so ... association between sunbed use and increased risks of melanoma, as ...
... are less likely to quit smoking, say international researchers. // ... came about through research involving the review of 31 previous ... study to analyze smoking patterns in Asia, Australia and New ... Institute for International Health , Sydney Australia and colleagues. ...
... of mostly older male veterans suffering from chronic obstructive pulmonary ... lung cancer, researchers found that regular use of high dose ... ,The results for this study appear in ... of Respiratory and Critical Care Medicine, published by the American ...
... they figure out the words' meaning for themselves, research by ... Brinster, an undergraduate student in the John Hopkins University and ... words by inference is more powerful for 3-year-olds than just ... things that is particularly exciting about the work Meredith is ...
... appropriate weight, according to current guidelines,// are four times ... have a baby who becomes overweight in early childhood. ... Department of Ambulatory Care and Prevention of Harvard Medical ... in the April issue of the American Journal of ...
Cached Medicine News:Health News:Obesity can Cause Asthma too 2Health News:Sultans of Suntans Warned 2Health News:Asian Smokers in Danger 2Health News:High-dose Inhaled Corticosteroid Use for COPD Could Cut Risk of Lung Cancer 2Health News:High-dose Inhaled Corticosteroid Use for COPD Could Cut Risk of Lung Cancer 3Health News:Learning Words by Inference More Powerful for Toddlers 2Health News:Weight Gain in Pregnancy Linked to Overweight in Kids 2Health News:Weight Gain in Pregnancy Linked to Overweight in Kids 3
The Biopro All Poly cup is a uniquely designed UHMWPE acetabular cup....
The Pe-Plus offers an additional clinical option for replacing the acetabulum....
BatCup cotyloid implant, designed for use in revision surgery, is an hemispherical metal cup, with grooves on the edges that house locking flanges, which are attached to the iliac bone by cancellous ...
The cementless acetabular shells form part of the Mallory head range of femoral and acetabular implants....
Medicine Products: